Respiratory Medicine Sales Soar in December Amidst Poor Air Quality, Seasonal Factors

• Respiratory medicine volumes doubled in December 2025, significantly outpacing the broader Indian pharmaceutical market (IPM).
• Growth was driven by poor air quality, seasonal factors, and increased chronic use of inhalers for asthma and COPD, especially in northern and urban India.
• Respiratory unit sales rose 5.2% compared to IPM's 2.6%, indicating true consumption rather than just price-driven increases.
• The respiratory segment, valued at Rs. 18,913 crore in 2025, represents 8% of the total IPM and recorded 10% value growth.
• Companies like Cipla, GSK, Glenmark, Lupin, and Zydus with inhaler-led portfolios are set for sustainable revenue visibility through 2026.

Why It Matters: Poor air quality and chronic conditions fueled a significant surge in respiratory medicine sales, especially inhalers, in December 2025.